NVCR
Companies
NASDAQ
Novocure Ltd.
Health Care
$16.80
-$13.00 (-43.62%)
Price Chart
Overview
About NVCR
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Market Cap
$2.3B
Volume
12.3M
Avg. Volume
16.4M
P/E Ratio
-10.246667
Dividend Yield
0.00%
Employees
1.3K
Company Information
Risk & Correlation Analysis
Market Correlation
1.92
High Correlation
Volatility
High (0.85)
Relative to market
Macro Factor Sensitivities
Interest Rates
Medium Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Low Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, NVCR shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$2.3B
Volume12.3M
P/E Ratio-10.25
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 2, 2024Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025